Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity

mAbs

Volumn 5, Issue 6, 2013, Pages 872-881

  Shatz, Whitney ^a   Chung, Shan ^a   Li, Bing ^a   Marshall, Brett ^a   Tejada, Max ^a   Phung, Wilson ^a   Sandoval, Wendy ^a   Kelley, Robert F ^a   Scheer, Justin M ^a  

^a GENENTECH INC   (United States)

Author keywords

ADCC; Afucosylation; Asymmetric antibody; Effector function; Glycosylation; Heterodimer; Knobs into holes; Symmetry

Indexed keywords

BISPECIFIC ANTIBODY; CD20 ANTIBODY; FC RECEPTOR; GLYCAN; HETERODIMER; HOMODIMER; MONOMER; SIALIC ACID; FUCOSE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BIOTECHNOLOGY; CARBOHYDRATE ANALYSIS; CONFORMATIONAL TRANSITION; DEGLYCOSYLATION; DIMERIZATION; EFFECTOR CELL; ELECTROPHORESIS; ENDOPLASMIC RETICULUM; FUCOSYLATION; GEL PERMEATION CHROMATOGRAPHY; GENE EXPRESSION SYSTEM; GENE MUTATION; GLYCOSYLATION; HEAVY CHAIN; HUMAN; HUMAN CELL; IN VITRO STUDY; KNOBS INTO HOLE TECHNOLOGY; LIGHT CHAIN; LIGHT SCATTERING; MAMMAL CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; RECEPTOR BINDING; ROOM TEMPERATURE; SIALYLATION; ANIMAL; CELL CULTURE; CELL LINE; CELL SURVIVAL; CHO CELL LINE; CRICETULUS; IMMUNOLOGY; METABOLISM; PROTEIN ENGINEERING;

ANIMALS; ANTIBODY FORMATION; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; CHO CELLS; CRICETULUS; DIMERIZATION; FUCOSE; GLYCOSYLATION; HUMANS; PROTEIN ENGINEERING;

EID: 84889850198     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.26307     Document Type: Article

References (35)

1. Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 2013; 31:753-8; PMID:23831709; http://dx.doi.org/10.1038/nbt.2621
2. Spigel DRET, Ramlau R, Daniel DB. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMab or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011; 29:suppl abstr 7505.
3. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677-81; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
4. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, Lee WP, Zhang J, Sharma N, Lu Y, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 2010; 285:20850-9; PMID:20444694; http://dx.doi.org/10.1074/jbc.M110. 113910
5. Deo YM, Graziano RF, Repp R, van de Winkel JG. Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today 1997; 18:127-35; PMID:9078685; http://dx.doi.org/10.1016/S0167-5699(97)01007-4
6. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 2001; 276:16469-77; PMID:11297532; http://dx.doi.org/10.1074/jbc.M100350200
7. Wright A, Morrison SL. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 1997; 15:26-32; PMID:9032990; http://dx.doi.org/10.1016/S0167-7799(96)10062-7
8. Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA. Glycosylation and the immune system. Science 2001; 291:2370-6; PMID:11269318; http://dx.doi.org/ 10.1126/science.291.5512.2370
9. Jefferis R, Lund J, Pound JD. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 1998; 163:59-76; PMID:9700502; http://dx.doi.org/10. 1111/j.1600-065X.1998.tb01188.x
10. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200
11. Ferrara C, Stuart F, Sondermann P, Brünker P, Umaña P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006; 281:5032-6; PMID:16330541; http://dx.doi.org/10.1074/jbc.M510171200
12. Hooijberg E, van den Berk PC, Sein JJ, Wijdenes J, Hart AA, de Boer RW, Melief CJ, Hekman A. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model. Cancer Res 1995; 55:840-6; PMID:7531616
13. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704
14. Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999; 17:176-80; PMID:10052355; http://dx.doi.org/10.1038/6179
15. Grillo-López AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol 2002; 29(Suppl 2):105-12; PMID:11842397; http://dx.doi.org/10.1053/sonc.2002.30145
16. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754
17. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-34; PMID:19247305; http://dx.doi.org/10.1038/nrd2804
18. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000; 406:267-73; PMID:10917521; http://dx.doi.org/10.1038/35018508
19. Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 2011; 108:12669-74; PMID:21768335; http://dx.doi.org/10.1073/pnas.1108455108
20. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 2004; 336:1239-49; PMID:15037082; http://dx.doi.org/10. 1016/j.jmb.2004.01.007
21. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200
22. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200
23. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004; 87:614-22; PMID:15352059; http://dx.doi.org/10.1002/bit.20151
24. Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu ZJ, Shen A, et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs 2012; 4:326-40; PMID:22531441; http://dx.doi.org/10.4161/mabs.19941
25. Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420:204-19; PMID:22543237; http://dx.doi.org/10.1016/j.jmb.2012.04.020
26. Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013; 110:5145-50; PMID:23479652; http://dx.doi.org/10.1073/pnas. 1220145110
27. Ha S, Ou Y, Vlasak J, Li Y, Wang S, Vo K, Du Y, Mach A, Fang Y, Zhang N. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. Glycobiology 2011; 21:1087-96; PMID:21470983; http://dx.doi.org/10.1093/glycob/ cwr047
28. Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, Masuda K, Satoh M, Kato K. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 2011; 16:1071-80; PMID:22023369; http://dx.doi.org/10.1111/j.1365-2443.2011.01552.x
29. Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem Biol 2012; 7:1596-602; PMID:22747430; http://dx.doi.org/10.1021/cb300130k
30. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003; 325:979-89; PMID:12527303; http://dx.doi.org/10.1016/S0022-2836(02)01250-0
31. Keen MJ, Rapson NT. Development of a serum-free culture medium for the large scale production of recombinant protein from a Chinese hamster ovary cell line. Cytotechnology 1995; 17:153-63; PMID:22358555; http://dx.doi.org/10.1007/ BF00749653
32. Bynum MA, Yin H, Felts K, Lee YM, Monell CR, Killeen K. Characterization of IgG N-glycans employing a microfluidic chip that integrates glycan cleavage, sample purification, LC separation, and MS detection. Anal Chem 2009; 81:8818-25; PMID:19807107; http://dx.doi.org/10.1021/ac901326u
33. Trojer L GK, van de Goor T, Buckenmaier S. The mAb-Glyco Chip Kit - a Workflow Solution for Rapid and Fully Automated Characterization of N-linked Glycans from Monoclonal Antibodies. Chromatography Today 2011; August/September:16-21.
34. Lu Y, Wong WL, Meng YG. A high throughput electrochemiluminescent cell-binding assay for therapeutic anti-CD20 antibody selection. J Immunol Methods 2006; 314:74-9; PMID:16814318; http://dx.doi.org/10.1016/j.jim.2006.05. 011
35. Schnueriger A, Grau R, Sondermann P, Schreitmueller T, Marti S, Zocher M. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol Immunol 2011; 48:1512-7; PMID:21570725; http://dx.doi.org/10.1016/j.molimm.2011.04.010